Cue Biopharma (CUE) Non Operating Income (2018 - 2025)
Cue Biopharma (CUE) posted Non Operating Income of -$199000.0 for Q4 2025, down 235.37% sequentially from $147000.0 in Q3 2025, and down 245.26% YoY from $137000.0 in Q4 2024.
Cue Biopharma (CUE) Non Operating Income (2018 - 2025) Analysis & Trends
Cue Biopharma has reported Non Operating Income for 8 years, with the latest figure at -$199000.0 in Q4 2025.
- Quarterly Non Operating Income fell 245.26% year-over-year to -$199000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $271000.0 (down 73.25% YoY) and the FY2025 annual result came in at $450000.0, down 45.52% from the prior year.
- Non Operating Income retreated to -$199000.0 in Q4 2025 per CUE's latest filing, from $147000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $1.6 million in Q4 2023 and troughed at -$199000.0 in Q4 2025.
- A 5-year average of $237094.9 and a median of $150000.0 in 2025 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2025: Non Operating Income jumped 6929.25% in 2022, then slumped 245.26% in 2025.
- Over 5 years, Non Operating Income stood at $3898.0 in 2021, then surged by 6929.25% to $274000.0 in 2022, then soared by 499.64% to $1.6 million in 2023, then tumbled by 91.66% to $137000.0 in 2024, then plunged by 245.26% to -$199000.0 in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered -$199000.0, $147000.0, and $153000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | -65.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -199,000.00 |
| Sep 30, 2025 | 147,000.00 |
| Jun 30, 2025 | 153,000.00 |
| Mar 31, 2025 | 170,000.00 |
| Dec 31, 2024 | 137,000.00 |
| Sep 30, 2024 | 343,000.00 |
| Jun 30, 2024 | 212,000.00 |
| Mar 31, 2024 | 321,000.00 |
| Dec 31, 2023 | 1.64 Mn |
| Sep 30, 2023 | 700,000.00 |
| Jun 30, 2023 | 332,000.00 |
| Mar 31, 2023 | 271,000.00 |
| Dec 31, 2022 | 274,000.00 |
| Sep 30, 2022 | 76,000.00 |
| Jun 30, 2022 | 88,000.00 |
| Mar 31, 2022 | 8,000.00 |
| Dec 31, 2021 | 3,898.00 |
| Sep 30, 2021 | 25,000.00 |
| Jun 30, 2021 | 24,000.00 |
| Mar 31, 2021 | 13,000.00 |